MYOVIEW

This brand name is authorized in United States. It is also authorized in Austria, Cyprus, Estonia, France, Hong Kong SAR China, Ireland, Japan, Lithuania, Malta, Singapore, Spain, UK.

Active ingredients

The drug MYOVIEW contains one active pharmaceutical ingredient (API):

1	Technetium ⁹⁹ᵐTc tetrofosmin UNII 42FOP1YX93 - TECHNETIUM TC-99M TETROFOSMIN
	Technetium (99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium according to myocardial perfusion and viability. It is used for Myocardial Perfusion Imaging and Ventricular Function Imaging.
	Read more about Technetium ⁹⁹ᵐTc tetrofosmin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYOVIEW Kit, Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09GA02	Technetium (99mTc) tetrofosmin	V Various → V09 Diagnostic radiopharmaceuticals → V09G Cardiovascular system → V09GA Technetium (99mTc) compounds
Discover more medicines within V09GA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1087130
ES	Centro de información online de medicamentos de la AEMPS	65010
FR	Base de données publique des médicaments	61360340
GB	Medicines & Healthcare Products Regulatory Agency	398418
HK	Department of Health Drug Office	42834
JP	医薬品医療機器総合機構	4300446D1024, 4300446G1020
LT	Valstybinė vaistų kontrolės tarnyba	1007286, 1017520
MT	Medicines Authority	MA023/00501
SG	Health Sciences Authority	11820P
US	FDA, National Drug Code	17156-026